Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 349 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Attention Control Clear all
Completed No phase listed Observational

Motor Cortex Reward Signaling in Parkinson Disease

NCT00558766
View directory record Official record
Conditions
Parkinson Disease
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
45 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 22, 2026, 5:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

An Evaluation of Neurofeedback Efficacy in Adults With ADHD

NCT01852357
View directory record Official record
Conditions
ADHD
Interventions
Neurofeedback, Sham Neurofeedback
Other
Lead sponsor
University of North Carolina, Wilmington
Other
Eligibility
18 Years to 40 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Oct 22, 2026, 5:33 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)

NCT03442764
View directory record Official record
Conditions
Non-obstructive Hypertrophic Cardiomyopathy
Interventions
mavacamten, Placebo
Drug
Lead sponsor
MyoKardia, Inc.
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
32
States / cities
Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Oct 22, 2026, 5:33 AM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder

NCT01552902
View directory record Official record
Conditions
Attention-deficit/Hyperactivity Disorder
Interventions
Lisdexamfetamine dimesylate, Methylphenidate Hydrochloride, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
13 Years to 17 Years
Enrollment
549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
81
States / cities
Dothan, Alabama • Tucson, Arizona • Little Rock, Arkansas + 68 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Oct 22, 2026, 5:33 AM EDT
Completed Phase 3 Interventional

P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety

NCT06973577
View directory record Official record
Conditions
ADHD, Anxiety, Generalized Anxiety, Social Anxiety Disorder
Interventions
Centanafadine, Placebo
Drug · Other
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
46
States / cities
Dothan, Alabama • Little Rock, Arkansas • Rogers, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 22, 2026, 5:33 AM EDT
Completed Phase 4 Interventional Results available

Mild Cognitive Impairment in Parkinson's Disease

NCT01519271
View directory record Official record
Conditions
Parkinson's Disease, Mild Cognitive Impairment
Interventions
Exelon Patch (rivastigmine transdermal system), Placebo Patches
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
40 Years to 85 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 7, 2017 · Synced Oct 22, 2026, 5:33 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Efficacy, Safety, and Tolerability of TC-5619 in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)

NCT01124708
View directory record Official record
Conditions
ADHD
Interventions
TC-5619-238, Placebo
Drug
Lead sponsor
Targacept Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
16
States / cities
Bradenton, Florida • Jacksonville, Florida • Lauderhill, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2013 · Synced Oct 22, 2026, 5:33 AM EDT
Terminated Phase 4 Interventional Results available

Effects of Evening Dose of Immediate Release Methylphenidate on Sleep in Children With ADHD

NCT02638168
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, Behavioral Insomnia of Childhood
Interventions
Immediate Release Methylphenidate, Placebo
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
6 Years to 12 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Oct 22, 2026, 5:33 AM EDT
Completed Phase 2 Interventional

A Safety and Effectiveness Study of JNJ-31001074 in Adults With Attention-Deficit/Hyperactivity Disorder.

NCT00566449
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Placebo, JNJ-31001074
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 64 Years · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
21
States / cities
Irvine, California • Lafayette, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 13, 2014 · Synced Oct 22, 2026, 5:33 AM EDT
Completed Phase 1 Interventional

Phase I Single Dose, Open-Label Pharmacokinetic Study and Single-Blind, Placebo-Controlled Dose Escalation Study of NFC-1 in Adolescents With Attention-Deficit Hyperactivity Disorder

NCT02286817
View directory record Official record
Conditions
Attention-deficit Hyperactivity Disorder (ADHD)
Interventions
NFC-1
Drug
Lead sponsor
Aevi Genomic Medicine, LLC, a Cerecor company
Industry
Eligibility
12 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 22, 2026, 5:33 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effect of Lutein, Zeaxanthin, and Meso-Zeaxanthin Supplementation on Skin Carotenoid Concentration: A Six-Month, Placebo-Controlled Crossover Study

NCT06965426
View directory record Official record
Conditions
Macular Degenerative Disease
Interventions
Lutein, Zeaxanthin, and Meso-Zeaxanthin Supplementation
Other
Lead sponsor
Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 22, 2026, 5:33 AM EDT
Completed Phase 2Phase 3 Interventional Results available

L-methylfolate Supplementation to OROS-Methylphenidate Pharmacotherapy in ADHD Adults

NCT01853280
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
L-methylfolate, OROS-Methylphenidate, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 22, 2026, 5:33 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder (ADHD)

NCT03260205
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
Placebo, SPD489 (Lisdexamfetamine dimesylate), SPD489
Drug
Lead sponsor
Shire
Industry
Eligibility
4 Years to 5 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
48
States / cities
Dothan, Alabama • Little Rock, Arkansas • Colton, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 22, 2026, 5:33 AM EDT
Completed Early Phase 1 Interventional

Study of the Effects of Oxytocin on Attentional Bias and Startle in PTSD

NCT03211013
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Oxytocin, Placebos
Drug
Lead sponsor
Palo Alto Veterans Institute for Research
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Menlo Park, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Oct 22, 2026, 5:33 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD

NCT04016779
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions
Placebo, SPN-812
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
37
States / cities
Garden Grove, California • Los Alamitos, California • Newport Beach, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Oct 22, 2026, 5:33 AM EDT
Completed No phase listed Observational

Glycemic Control Based on Serum Fructosamine Concentration vs. hemoglobinA1c (HbA1c) in Diabetic Patients

NCT04079660
View directory record Official record
Conditions
Diabetes
Interventions
Capillary blood glucose blood draw
Diagnostic Test
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Timeline
2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Oct 22, 2026, 5:33 AM EDT
Recruiting Not applicable Interventional

Regulating Emotions Like An eXpert Among Adolescents With ADHD

NCT06725186
View directory record Official record
Conditions
RELAX Telehealth Intervention, Psychoeducational Waitlist Control, EMI Smartphone App Pilot
Interventions
RELAX, Psychoeducational Materials
Behavioral
Lead sponsor
Virginia Polytechnic Institute and State University
Other
Eligibility
11 Years to 16 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Blacksburg, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 22, 2026, 5:33 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Control of Cognition (Naltrexone, Methylphenidate, and ADHD Study (NMAS))

NCT01993108
View directory record Official record
Conditions
Healthy, Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate, Naltrexone, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 35 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Oct 22, 2026, 5:33 AM EDT
Completed Not applicable Interventional

Attention Control Training for PTSD in Children

NCT03348540
View directory record Official record
Conditions
PTSD
Interventions
Attention Control Training, Comparison Task
Behavioral
Lead sponsor
Creighton University
Other
Eligibility
7 Years to 15 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Oct 22, 2026, 5:33 AM EDT
Completed Not applicable Interventional

Tai Chi Training for Children With ADHD

NCT02234557
View directory record Official record
Conditions
ADHD
Interventions
Tai Chi
Behavioral
Lead sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Other
Eligibility
8 Years to 12 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 22, 2026, 5:33 AM EDT
Completed Phase 3 Interventional Results available

Non-inferiority Study of Safety and Efficacy of Everolimus With Low Dose Tacrolimus to Mycophenolate Mofetil With Standard Dose Tacrolimus in Kidney Transplant Recipients

NCT01025817
View directory record Official record
Conditions
Kidney Transplant
Interventions
Everolimus and tacrolimus, mycophenolate mofetil and tacrolimus
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
613 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
48
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2015 · Synced Oct 22, 2026, 5:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose Study to Assess the Safety, Tolerability, Concentration in Body and Effect of BAF312

NCT00422175
View directory record Official record
Conditions
Healthy
Interventions
BAF 312
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 29, 2007 · Synced Oct 22, 2026, 5:33 AM EDT
Completed Phase 3 Interventional Results available

A Trial to Evaluate the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder

NCT03605836
View directory record Official record
Conditions
Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder
Interventions
Centanafadine SR, Placebo
Drug · Other
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced Oct 22, 2026, 5:33 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Efficacy and Safety Study in Adults With ADHD Using CTx-1301.

NCT05631626
View directory record Official record
Conditions
ADHD, ADHD - Combined Type, Attention Deficit Hyperactivity Disorder Combined, Attention Deficit Hyperactivity Disorder
Interventions
CTx-1301 - Dexmethylphenidate 25mg, CTx-1301 - Dexmethylphenidate 37.5mg, CTx-1301 - Dexmethylphenidate 50mg, Placebo
Drug
Lead sponsor
Cingulate Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 22, 2026, 5:33 AM EDT